PROMIS was registered on ClinicalTrials.gov (NCT01292291), and its design has been discussed elsewhere [6]. In brief, this was a multicentre study in which biopsy-naïve men with PSA ≤15 ng/mL underwent prebiopsy 1.5 T mpMRI, followed by a combined biopsy procedure under general anaesthetic. The combined procedure consisted of 5 mm transperineal template mapping (TPM) biopsy followed by standard systematic TRUS-guided biopsy. Each test was performed and reported by clinicians blinded to other results. For this work, only men enrolled at University College London Hospital (UCLH) were considered (n = 235).

Ethical approval for PROMIS was granted by the National Research Ethics Service Committee London (Ref: 11/LO/0185).

Note: The content above has been extracted from a research article, so it may not display correctly.



Q&A
Please log in to submit your questions online.
Your question will be posted on the Bio-101 website. We will send your questions to the authors of this protocol and Bio-protocol community members who are experienced with this method. you will be informed using the email address associated with your Bio-protocol account.



We use cookies on this site to enhance your user experience. By using our website, you are agreeing to allow the storage of cookies on your computer.